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Introduction 
Desmoplastic melanoma (DM) is a rare form of malignant melanoma, accounting for 
less than 4% of all primary melanomas often associated with lentigo maligna (Bastos 
Junior et al., 2013). Due to its amelanotic and atypical appearance it is commonly 
mistaken for a benign tumor, an inflammatory condition or non-melanocytic spindle 
cell proliferation including squamous cell carcinoma and dermatofibroma.(Busam et 
al., 2004)  
Case Description 
A 52 year old male presented himself at the Emergency Department of the Medical 
University of Graz due to a coughing attack with pain in his right thoracic side. X-ray 
revealed a fracture of the 10th right rib and a lesion in the right middle lobe. 
Subsequent chest CT-scan showed3.5 cm diameter hyperdense inhomogeneous 
lesion as well as several enlarged hilar lymph nodes. These results were confirmed 
by a PET-CT scan with no additional metabolically active lesions. The tissue obtained 
by a transthoracic biopsy was highly positive for S-100, Melan-A and HMB-45. The 
antigenic profile of the lesion in conjunction with its histopathological morphology 
lead to the diagnosis of a DM metastasis. No mutations were found in BRAF, EGFR, 
ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53. However, an 
activating mutation which is mainly found as hotspot mutation in familial 
neuroblastoma (Mossé et al., 2008) was found in ALKR1275Q. The patient was referred 
to the Department of Dermatology for therapy. Whole body examination could identify 
no clinically or dermatologically suspicious lesions in chronic sun damaged skin. The 
patient was enrolled in a clinical trial with pembrolizumab, which was administered at 
a dose of 10 mg kg-1 every 2 weeks. The patient had a partial response. After five 
months of therapy, a change in color and shape of a pre-existent brown lesion on the 
left frontal side was noticed (Figure 1). A punch biopsy confirmed the diagnosis of 
melanoma. The whole lesion was removed. Histopathology revealed a 2.5 mm 
(AJCC: 2009: T3a) thick lentigo maligna lesion with desmoplastic melanoma. 
Immunohistochemical staining (Figure 2) with monoclonal antibodies (Pellegrino et 
al., 1982; Sernee et al., 1998; Stam et al., 1986; Wang et al., 2005) showed HLA 
class I heavy chain and beta2-microglobulin expression, but did not detect 
transporter associated with antigen processing (TAP2) and tapasin. Following a two 
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year treatment with pembrolizumab the patient had a complete response which has 
been ongoing for 36 months. 
 
Discussion 
An occult (dormant) primary desmoplastic melanoma tumor grew in a patient under 
treatment with pembrolizumab, although the latter had induced regression of 
metastases. These apparently conflicting findings may reflect the outgrowth in a 
primary tumor of malignant cells which have been “awakened” from their dormancy 
and escape immune destruction because of abnormalities in HLA class I antigen 
processing machinery. The latter cause a defective tumor antigen presentation to 
cognate T cells. If our interpretation is correct, our results have identified a novel type 
of resistance to checkpoint inhibitor-based therapy.  
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Figures 
Figure 1. Clinical and dermoscopic images of the desmoplastic melanoma after anti-
PD-1 treatment.  
 
(a) Image from the left frontal side taken and provided by the patient four months 
prior to the diagnosis of desmoplastic metastatic melanoma. 
(b) Image taken five months after induction of immunotherapy. The suspect lesion on 
the left fronto-occipital border changed in color from light brown to dark brown. 
Dermoscopic image of the desmoplastic melanoma: irregular dark brown streaks in a 
fair brown pigmented lesion.  
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Figure 2. Immunhistochemical image of the desmoplastic melanoma.  
 
Histopathological picture of the desmoplastic melanoma which was removed after 
revelation during immunotherapy. Haematoxylin/Eosin (HE) staining with 
immunohistochemical staining against HLA class I heavy chains (+), beta2-
microglobuline (+),TAP2 (-) and tapasin (-), respectively. Original magnification 12x 
and in the lower left corner original magnification 19.6x. 
 
